Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Danson

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2009
Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancerEmma Dean, Duncan Jodrell, Kate Connolly, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2013
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)Mary E R O'Brien, Rabab M Gaafar, Sanjay Popat, et al.
Cancer|July 25, 2003
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinomaSarah Danson, Mark R Middleton, Kenneth J O'Byrne, et al.
Clinical Chemistry|June 27, 2018
Genome-Wide Analysis of Circulating Cell-Free DNA Copy Number Detects Active Melanoma and Predicts SurvivalShobha Silva, Sarah Danson, Dawn Teare, et al.
Trials|April 20, 2018
CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trialDean A Fennell, Emma Kirkpatrick, Kelly Cozens, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2016
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLCEdurne Arriola, Matthew Wheater, Ian Galea, et al.
British Journal of Cancer|April 29, 2023
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancerRebecca Kristeleit, Ruth Plummer, Robert Jones, et al.
Oncoimmunology|May 10, 2019
Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancerMax Hardy-Werbin, Pedro Rocha, Oriol Arpi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2014
Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II studyRonald Natale, Fiona Blackhall, Dariusz Kowalski, et al.
Eclinicalmedicine|June 16, 2022
Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trialDean A Fennell, Catharine Porter, Jason Lester, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2009
Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancerEmma Dean, Duncan Jodrell, Kate Connolly, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2013
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)Mary E R O'Brien, Rabab M Gaafar, Sanjay Popat, et al.
Cancer|July 25, 2003
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinomaSarah Danson, Mark R Middleton, Kenneth J O'Byrne, et al.
Clinical Chemistry|June 27, 2018
Genome-Wide Analysis of Circulating Cell-Free DNA Copy Number Detects Active Melanoma and Predicts SurvivalShobha Silva, Sarah Danson, Dawn Teare, et al.
Trials|April 20, 2018
CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trialDean A Fennell, Emma Kirkpatrick, Kelly Cozens, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2016
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLCEdurne Arriola, Matthew Wheater, Ian Galea, et al.
British Journal of Cancer|April 29, 2023
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancerRebecca Kristeleit, Ruth Plummer, Robert Jones, et al.
Oncoimmunology|May 10, 2019
Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancerMax Hardy-Werbin, Pedro Rocha, Oriol Arpi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2014
Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II studyRonald Natale, Fiona Blackhall, Dariusz Kowalski, et al.
Eclinicalmedicine|June 16, 2022
Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trialDean A Fennell, Catharine Porter, Jason Lester, et al.
Pageof 7